C
Csaba Szabó
Researcher at Eötvös Loránd University
Publications - 1001
Citations - 67591
Csaba Szabó is an academic researcher from Eötvös Loránd University. The author has contributed to research in topics: Nitric oxide & Poly ADP ribose polymerase. The author has an hindex of 123, co-authored 958 publications receiving 61791 citations. Previous affiliations of Csaba Szabó include University of Texas Medical Branch & University of Fribourg.
Papers
More filters
Journal ArticleDOI
Peroxynitrite: biochemistry, pathophysiology and development of therapeutics
TL;DR: This Review focuses on pharmacological strategies to attenuate the toxic effects of peroxynitrite, which include its catalytic reduction to nitrite and its isomerization to nitrate by metalloporphyrins, which have led to potential candidates for drug development for cardiovascular, inflammatory and neurodegenerative diseases.
Journal ArticleDOI
Hydrogen sulphide and its therapeutic potential
TL;DR: The physiology and biochemistry of H2S is overviews, the effects of H 2S inhibitors or H2s donors in animal models of disease are summarized, the potential options for the therapeutic exploitation of H1S are outlined and they are outlined.
Journal ArticleDOI
The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors
László Virág,Csaba Szabó +1 more
TL;DR: The double-edged sword roles of PARP in DNA damage signaling and cell death are reviewed and the underlying mechanisms of the anti-inflammatory effects ofPARP inhibitors are summarized.
Journal ArticleDOI
Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol
TL;DR: A critical overview of the effects of XO inhibitors in various pathophysiological conditions is presented and the various emerging therapeutic strategies offered by this approach are reviewed.
Journal ArticleDOI
Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function
John W. Elrod,John W. Calvert,Joanna Morrison,Jeannette E. Doeller,David W. Kraus,Ling Tao,Xiangying Jiao,Rosario Scalia,Levente Kiss,Csaba Szabó,Hideo Kimura,Chi Wing Chow,David J. Lefer +12 more
TL;DR: It is demonstrated that the delivery of H2S at the time of reperfusion limits infarct size and preserves left ventricular (LV) function in an in vivo model of myocardial ischemia-reperfusion (MI-R) and that either administration of H 2S or the modulation of endogenous production may be of clinical benefit in ischemic disorders.